Email this article 
In the paper, the results of 1-year treatment with avonex, a new immunomodulator from the group of interferons b, in 34 patients with relapsing remitting multiple sclerosis have been reported. In the treated patients it was shown significant decrease of the activity of the pathological process, which was evidenced by reduction of the severity of exacerbations and the relapse rate. The decrease of disability of patients with multiple sclerosis (by EDSS score) was revealed. In general, one can notice good tolerability of avonex.
Study of the effectiveness of avonex in multiple sclerosis (1-year treatment)
- Authors: Zavalishin I.A.1, Peresedova A.V.1, Stoida N.I.1, Askarova L.S.1, Zakharova M.N.1, Adarcheva L.S.2, Niyazbekova A.S.3, Trifonova O.V.1, Rebrova O.Y.3, Eliseeva D.D.3
-
Affiliations:
- Research Center of Neurology
- Research Center of Neurology, Russian Academy of Medical Sciences,
- Research Center of Neurology, Russian Academy of Medical Sciences
- Issue: Vol 3, No 3 (2009)
- Pages: 21-24
- Section: Original articles
- URL: https://www.annaly-nevrologii.com/journal/pathID/article/view/366
- DOI: https://doi.org/10.17816/psaic366
- ID: 366
Cite item
Full Text
Abstract
Keywords
About the authors
I. A. Zavalishin
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
A. V. Peresedova
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
N. I. Stoida
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Моscow
Lola Sh. Askarova
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
Maria N. Zakharova
Research Center of Neurology
Email: neuro_inf@neurology.ru
ORCID iD: 0000-0002-1072-9968
SPIN-code: 4277-2860
D. Sci. (Med.), principal researcher, Head, 6th Neurological department, Institute of Clinical and Preventive Neurology
Russian Federation, MoscowL. S. Adarcheva
Research Center of Neurology, Russian Academy of Medical Sciences,
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
A. S. Niyazbekova
Research Center of Neurology, Russian Academy of Medical Sciences
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
Olga V. Trifonova
Research Center of Neurology
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
O. Yu. Rebrova
Research Center of Neurology, Russian Academy of Medical Sciences
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
D. D. Eliseeva
Research Center of Neurology, Russian Academy of Medical Sciences
Author for correspondence.
Email: neuro_inf@neurology.ru
Russian Federation, Moscow
References
- Biernacki K., Antel J.P., Blain M. et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 2005; 62: 563–568.
- Boutros T., Croze E., Yong V.W. Interferon-β is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 1997; 69: 939–946.
- Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol. Sci. 2008; 29 (Suppl. 2): S253–255.
- Farrell R., Kapoor R., Leary S. et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of InterferonПbeta. Mult. Sclerоsis 2008; 14: 212–218.
- Gneiss C., Tripp P., Reichartseder F. et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult. Scler. 2006; 12: 731–737.
- Goodin D.S., Frohman E.M., Hurwitz B. et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977–984.
- Jacobs L.D., Cookfair D.L., Rudick R.A. et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann. Neurol. 1996; 39: 285–294.
- Rudick R.A., Goodkin D.E., Jacobs L.D. et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Neurology 1997; 49: 358–363.
- Simon J.H., Jacobs L.D., Campion M. et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann. Neurol. 1996; 43: 79–87.
- Sorensen P.S., Deisenhammer F., Duda P. et al. Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Europ. J. Neurol. 2005; 12: 817–827.
- Zidanov R., Locatelli L., Cookfair D. et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult. Sclerosis 2007; 13: 490–501.
- Zidanov R., Munschauer F.E., Ramanathan M. et al. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon beta-1a in patients with MS and CIS. Drugs Today (Barc.) 2008; 44: 601–613.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).